Company Analysis

Dermata Therapeutics, Inc. (DRMA)

Nasdaq: DRMA · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2021
Grade5.7
◀ Past 6.0● Present 4.5▶ Future 6.6
6 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

1 patent granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Dermata Therapeutics, Inc.’s names, not what it holds today.

Patents granted
1
1 utility, 1976 to Dec 31, 2025
Granted in 2025
1
in the last year the record reads
Applications published
6
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'22'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
DERMATA THERAPEUTICS, INC. its own name
named as the applicant on its applications, in US
0 granted
6 published
DERMATA THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
1 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jan 28, 202512,208,123Compositions and methods for the treatment of skin conditionsPharmaceuticalsDERMATA THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Apr 10, 20252025/0114408COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSPharmaceuticalsDERMATA THERAPEUTICS, INC.
Apr 3, 20252025/0108074COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONSPharmaceuticalsDERMATA THERAPEUTICS, INC.
Mar 28, 20242024/0099962COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSOrganic fine chemistryDERMATA THERAPEUTICS, INC.
Sep 15, 20222022/0288133COMPOSITIONS FOR THE TREATMENT OF CONDITIONS BY DERMAL FILLERSMedical technologyDERMATA THERAPEUTICS, INC.
Jun 9, 20222022/0175660COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSOrganic fine chemistryDERMATA THERAPEUTICS, INC.
Apr 21, 20222022/0118029COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONSPharmaceuticalsDERMATA THERAPEUTICS, INC. · patent 12,208,123 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 2 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton DRMA · research, not advice